AveXis Inc (AVXS) Set to Announce Earnings on Wednesday
AveXis Inc (NASDAQ:AVXS) is set to post its quarterly earnings results after the market closes on Wednesday, August 9th. Analysts expect AveXis to post earnings of ($1.06) per share for the quarter.
AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, May 11th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.13. During the same quarter in the prior year, the firm posted ($1.24) earnings per share. On average, analysts expect AveXis to post $-4.27 EPS for the current fiscal year and $-4.27 EPS for the next fiscal year.
Shares of AveXis Inc (NASDAQ AVXS) opened at 97.05 on Tuesday. The stock’s market capitalization is $2.70 billion. The firm has a 50-day moving average price of $80.67 and a 200-day moving average price of $71.89. AveXis Inc has a 1-year low of $31.55 and a 1-year high of $97.77.
Several research analysts recently commented on the company. Jefferies Group LLC reissued a “buy” rating and set a $92.00 target price on shares of AveXis in a research note on Wednesday, April 19th. Chardan Capital set a $103.00 price objective on AveXis and gave the stock a “buy” rating in a research report on Sunday, June 18th. Sanford C. Bernstein assumed coverage on AveXis in a research report on Thursday, July 27th. They set an “outperform” rating and a $108.00 price objective for the company. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Finally, Citigroup Inc. assumed coverage on AveXis in a research report on Tuesday, May 23rd. They set a “buy” rating and a $90.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $93.60.
In other news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $81.88, for a total transaction of $145,746.40. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $145,746.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 5,340 shares of company stock valued at $434,872. Insiders own 18.60% of the company’s stock.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.